318 related articles for article (PubMed ID: 30594678)
21. QSAR modeling to design selective histone deacetylase 8 (HDAC8) inhibitors.
Cao GP; Thangapandian S; Son M; Kumar R; Choi YJ; Kim Y; Kwon YJ; Kim HH; Suh JK; Lee KW
Arch Pharm Res; 2016 Oct; 39(10):1356-1369. PubMed ID: 27542119
[TBL] [Abstract][Full Text] [Related]
22. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
Kashyap K; Kakkar R
J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
[TBL] [Abstract][Full Text] [Related]
23. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
Debnath S; Debnath T; Bhaumik S; Majumdar S; Kalle AM; Aparna V
Sci Rep; 2019 Nov; 9(1):17174. PubMed ID: 31748509
[TBL] [Abstract][Full Text] [Related]
24. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.
Krennhrubec K; Marshall BL; Hedglin M; Verdin E; Ulrich SM
Bioorg Med Chem Lett; 2007 May; 17(10):2874-8. PubMed ID: 17346959
[TBL] [Abstract][Full Text] [Related]
25. Potent and Selective Non-hydroxamate Histone Deacetylase 8 Inhibitors.
Kleinschek A; Meyners C; Digiorgio E; Brancolini C; Meyer-Almes FJ
ChemMedChem; 2016 Dec; 11(23):2598-2606. PubMed ID: 27860422
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity.
Pidugu VR; Yarla NS; Pedada SR; Kalle AM; Satya AK
Bioorg Med Chem; 2016 Nov; 24(21):5611-5617. PubMed ID: 27665180
[TBL] [Abstract][Full Text] [Related]
27. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
Wang DF; Helquist P; Wiech NL; Wiest O
J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
[TBL] [Abstract][Full Text] [Related]
28. Discovery of the first histone deacetylase 6/8 dual inhibitors.
Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB
J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185
[TBL] [Abstract][Full Text] [Related]
29. Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine.
Muth M; Jänsch N; Kopranovic A; Krämer A; Wössner N; Jung M; Kirschhöfer F; Brenner-Weiß G; Meyer-Almes FJ
Biochim Biophys Acta Gen Subj; 2019 Mar; 1863(3):577-585. PubMed ID: 30611847
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity.
Trivedi P; Adhikari N; Amin SA; Bobde Y; Ganesh R; Jha T; Ghosh B
Eur J Pharm Sci; 2019 Oct; 138():105046. PubMed ID: 31421254
[TBL] [Abstract][Full Text] [Related]
31. Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity.
Lecointre B; Narozny R; Borrello MT; Senger J; Chakrabarti A; Jung M; Marek M; Romier C; Melesina J; Sippl W; Bischoff L; Ganesan A
Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685969
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase 8 in neuroblastoma tumorigenesis.
Oehme I; Deubzer HE; Wegener D; Pickert D; Linke JP; Hero B; Kopp-Schneider A; Westermann F; Ulrich SM; von Deimling A; Fischer M; Witt O
Clin Cancer Res; 2009 Jan; 15(1):91-9. PubMed ID: 19118036
[TBL] [Abstract][Full Text] [Related]
33. A comparative quantitative structural assessment of benzothiazine-derived HDAC8 inhibitors by predictive ligand-based drug designing approaches.
Banerjee S; Baidya SK; Adhikari N; Jha T
SAR QSAR Environ Res; 2022 Dec; 33(12):987-1011. PubMed ID: 36533308
[TBL] [Abstract][Full Text] [Related]
34. Kinetically selective and potent inhibitors of HDAC8.
Schweipert M; Jänsch N; Sugiarto WO; Meyer-Almes FJ
Biol Chem; 2019 May; 400(6):733-743. PubMed ID: 30521473
[TBL] [Abstract][Full Text] [Related]
35. A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors.
Fontana A; Cursaro I; Carullo G; Gemma S; Butini S; Campiani G
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077415
[TBL] [Abstract][Full Text] [Related]
36. Structure-activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery.
Amin SA; Adhikari N; Jha T
Future Med Chem; 2017 Dec; 9(18):2211-2237. PubMed ID: 29182018
[TBL] [Abstract][Full Text] [Related]
37. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
38. Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme.
Singh RK; Suzuki T; Mandal T; Balsubramanian N; Haldar M; Mueller DJ; Strode JA; Cook G; Mallik S; Srivastava DK
Biochemistry; 2014 Dec; 53(48):7445-58. PubMed ID: 25407689
[TBL] [Abstract][Full Text] [Related]
39. Preparation of a new construct of human histone deacetylase 8 for the crystallization of enzyme-inhibitor complexes.
Porter NJ; Christianson DW
Methods Enzymol; 2019; 626():561-585. PubMed ID: 31606091
[TBL] [Abstract][Full Text] [Related]
40. Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases.
Chakrabarti A; Melesina J; Kolbinger FR; Oehme I; Senger J; Witt O; Sippl W; Jung M
Future Med Chem; 2016 Sep; 8(13):1609-34. PubMed ID: 27572818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
